glucarpidase: Clinical Trials

15 trials of glucarpidase, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 terminated, 2 unknown, 1 active not recruiting. 7 Phase 2, 4 Phase 1, 2 Early Phase 1, 1 Not applicable, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Terminated 4, Completed 2, Suspended 1
Phase 14Completed 2, Terminated 1, Unknown 1
Early Phase 12Active not recruiting 1, Completed 1
Not applicable1Completed 1
Phase 31Completed 1

Follow glucarpidase: new trials by email Literature Review of glucarpidase trials Research Report on glucarpidase

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma
Glucarpidase, Methotrexate (MTX) - Primary Central Nervous System Lymphoma
Phase 1UnknownAssistance Publique - Hôpitaux de Paris182022-09-152022-10-25
Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate
High-dose methotrexate, Glucarpidase - Acute Kidney Injury, Drug Toxicity
UnknownProtherics Medicines Development Limited10002022-04-012024-05-10
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Glucarpidase 1000 UNT [Voraxaze] - Diffuse Large B-Cell Lymphoma, Drug Toxicity
Phase 2TerminatedFundacion CRIS de Investigación para Vencer el Cáncer32021-07-192024-05-13
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
Glucarpidase - Lymphoma
Phase 2SuspendedFox Chase Cancer Center32021-04-162024-03-22
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
Glucarpidase, Quality-of-Life Assessment - Osteosarcoma
Early Phase 1CompletedOHSU Knight Cancer Institute112019-03-272026-07-07
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
Methotrexate, Rituximab, leucovorin - Central Nervous System Lymphoma
Early Phase 1Active not recruitingMemorial Sloan Kettering Cancer Center582018-11-142026-04-15
High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma
glucarpidase, leucovorin - Osteosarcoma
Phase 2TerminatedBTG International Inc.72008-10-012014-09-15
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
Glucarpidase - Acute Lymphoblastic Leukemia (ALL)
Phase 3CompletedNordic Society for Pediatric Hematology and Oncology472008-07-012018-09-28
Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
glucarpidase, leucovorin calcium, methotrexate - Chemotherapeutic Agent Toxicity, Lymphoma
Phase 1 / Phase 2CompletedUniversity College, London42008-07-012014-01-27
Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze
glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin - Osteosarcoma, Leukemia
Phase 1CompletedBTG International Inc.202008-05-012022-06-06
Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
Glucarpidase, Methotrexate, Folinic Acid - Osteosarcoma, Spindle Cell Sarcoma of Bone
Phase 2TerminatedUniversity College, London342007-07-012015-06-04
Voraxaze for Delayed Methotrexate Clearance
Voraxaze (Glucarpidase), Placebo - Hematologic Malignancy, Solid Tumor
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center32007-01-012012-12-06
Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance
glucarpidase (50 Units/kg) - Neoplasms
Phase 2CompletedBTG International Inc.2000-01-012014-09-11
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
glucarpidase - Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Not applicableCompletedNational Cancer Institute (NCI)101993-11-012015-04-30
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
Voraxaze (glucarpidase) - Neoplasms
Approved for marketingBTG International Inc.2014-01-17

Conditions studied

Osteosarcoma (6)  ·  Lymphoma (4)  ·  Renal Insufficiency (3)  ·  Drug-Related Side Effects and Adverse Reactions (2)  ·  Hematologic Neoplasms (2)  ·  Leukemia (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Mucositis (2)  ·  Neoplasms (2)  ·  Neurotoxicity Syndromes (2)  ·  Acute Kidney Injury (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Recurrence (1)  ·  Water Intoxication (1)

Sponsors

BTG International Inc. (4)  ·  University College, London (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Fox Chase Cancer Center (1)  ·  Fundacion CRIS de Investigación para Vencer el Cáncer (1)  ·  M.D. Anderson Cancer Center (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  Nordic Society for Pediatric Hematology and Oncology (1)  ·  OHSU Knight Cancer Institute (1)  ·  Protherics Medicines Development Limited (1)

Countries

United States (6)  ·  France (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Canada (1)  ·  Denmark (1)  ·  Finland (1)  ·  Germany (1)  ·  Iceland (1)  ·  Italy (1)  ·  Norway (1)  ·  Sweden (1)  ·  Switzerland (1)

Top investigators

Adolfo De la Fuente, PD (1)  ·  Andrew Saunders, MD (1)  ·  Brigitte C. Widemann, MD (1)  ·  Carmelo Rizzari, MD (1)  ·  Christopher Ryan (1)  ·  Jeremy Whelan, Professor (1)  ·  Jesper Heldrup, M D (1)  ·  Lauren Schaff, MD (1)  ·  Paul Litka, MD (1)  ·  Pete Anderson, MD, PhD (1)  ·  Roderick Johnson, MD (1)  ·  Saroj Vadhan-Raj, MD (1)  ·  Suzanne Kincaid, CCRA (1)  ·  Thiel Eckhard, Prof. Dr.med. (1)

Results publications

PMID 15494606, PMID 27966809, PMID 35027038, PMID 38917404